As of February, 6 Evofem Biosciences, Inc. (EVFM) Analysts See $-0.43 EPS

Evofem Biosciences, Inc. (NASDAQ:EVFM)’s earnings release is expected by WallStreet on February, 6, as reported by RTT. After $-0.71 EPS report last quarter, Wall Street now forecasts -39.44 % EPS growth of Evofem Biosciences, Inc.. EVFM reached $3.86 during the last trading session after $0.1301 change.Currently Evofem Biosciences, Inc. is downtrending after 50.64% change in last January 10, 2018. EVFM has also 52,450 shares volume. The stock underperformed the S&P500 by 50.64%.

Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women.The firm is valued at $99.85 million. The company's product includes, Amphora contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections, and antimicrobial drug product to prevent the reoccurrence of bacterial vaginosis.Last it reported negative earnings. It also offers AMPOWER clinical research study, Chlamydia/Gonorrhea prevention clinical trial, and reduction in the recurrence of bacterial vaginosis clinical trial.

For more Evofem Biosciences, Inc. (NASDAQ:EVFM) news released briefly go to: Nasdaq.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Mid-Morning Market Update: Markets Open Lower; Hitachi To Acquire ABB’s Power-Grid Unit – Nasdaq” released on December 17, 2018, “Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” on November 10, 2018, “Wall Street Sees Another Round of Losses After Friday’s Selloff – Nasdaq” with a publish date: December 17, 2018, “The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte – Nasdaq” and the last “Evofem advancing Amphora gel for prevention of certain STDs in women; shares ahead 15% – Seeking Alpha” with publication date: August 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.